Aligos Therapeutics (NASDAQ:ALGS) Issues Quarterly Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) announced its earnings results on Friday. The company reported ($2.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.28) by $0.19, FiscalAI reports. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $4.85 million.

Aligos Therapeutics Price Performance

ALGS traded down $0.44 on Friday, reaching $4.07. 101,665 shares of the company traded hands, compared to its average volume of 130,776. The company has a market cap of $25.42 million, a price-to-earnings ratio of -0.56 and a beta of 2.43. The stock’s 50 day moving average price is $5.37 and its 200-day moving average price is $6.19. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ALGS. HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Weiss Ratings downgraded Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Finally, Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.